Cambridge Heart - Thank You

	Cambridge Heart Reports Results for the Second Quarter 2008
	Cambridge Heart Welcomes Louis Blumberg to the Board of Directors
	Microvolt T-Wave Alternans Found to Be Highly Accurate Predictor...
	CMS Reaffirms National Coverage Determination For Microvolt T-Wave Alternans
	Cambridge Heart Reports Results for the First Quarter 2008
	Medicare Coverage for Microvolt T-Wave Alternans Testing; Patented Analytic Spectral Method Required
	Premera Blue Cross Covers Microvolt T-Wave Alternans Testing
	Cambridge Heart Releases Statement by Dr. Theodore Chow on MTWA Testing
	ALPHA Supports Use of MTWA Risk Stratification in Non-Ischemic Heart Failure
	Largest Prospective Study of Microvolt T-Wave Alternans in Patients with Non-ischemic Cardiomyopathy Confirms the Predictive Value of MTWA
	Largest Prospective Study of Microvolt T-Wave Alternans Demonstrates This Technology's Predictive Value
	Clinical Trial Demonstrates that MTWA Test is Comparable to Invasive Tests in Identifying Patients Who Could Benefit from ICDs
	Read the article from Nature Clinical Practice Cardiovascular Medicine, ?Can microvolt T-wave alternans testing reduce unnecessary defibrillator implantation??
	More news...

Your Information Has Been Submitted
Thank You for Your Interest
in Cambridge Heart